NurExone Biologic Inc. NRXBF
0.35 USD -0.01 (-3.28%)
At closeNov 11, 2026, 4:00 PM EST
0.3515 Day range 0.3515
0.3002 52-week range 0.535
- YTD
- -29.23%
- 1 year
- -30.38%
News
globenewswire.com NurExone Demonstrates Consistent Anti-Inflammatory Activity Across Three Separate Batches of Exosomes New results strengthen the foundation for commercial naïve exosome supply and continued development of ExoPTEN New results strengthen the foundation for commercial naïve exosome supply and continued…
globenewswire.com NurExone Demonstrates Scalable Exosome Production, Supporting Its Modular Manufacturing Strategy and Commercial Growth TORONTO and HAIFA, Israel, Oct. 22, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing…
globenewswire.com NurExone Expands U.S. Engagement Across Four Major Boston Life Sciences Events and Provides Corporate Update CEO Dr. Lior Shaltiel and R&D Director Dr. Tali Kizhner to engage with industry, investors and scientific leaders during a concentrated week in Boston CEO Dr. Lior Shaltiel and R&D Director Dr. Tali…
globenewswire.com NurExone Announces Voting Results of Annual General and Special Meeting of Shareholders and Provides Corporate Update Shareholders grant the Board discretionary authority to implement a share consolidation of up to 30:1 Shareholders grant the Board discretionary authority to implement a share consolidation of up to…
globenewswire.com NurExone and NanoPass Technologies Ltd. to Collaborate on Integrated Exosome Delivery Approach for Regenerative Eye and Skin Applications Collaboration to evaluate MicronJet™ with NurExone exosomes across ophthalmic and aesthetic applications in multi-billion-dollar markets Collaboration to evaluate MicronJet™ with NurExone exosomes…
globenewswire.com NurExone Biologic Inc. Announces Second Quarter 2026 Financial Results TORONTO and HAIFA, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biotechnology company developing…
globenewswire.com NurExone Biologic Inc. to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference TORONTO and HAIFA, Israel, Aug. 28, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biotechnology company developing…
globenewswire.com NurExone Announces Annual General and Special Meeting to Consider Share Consolidation in Support of U.S. Capital Markets Strategy Proposed share consolidation of up to 30:1 intended to support potential U.S. exchange listing and broaden investor appeal
globenewswire.com NurExone Announces Closing of C$1,066,078 Private Placement TORONTO, and HAIFA, Israel, Aug. 21, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing…
globenewswire.com NurExone Reports New Preclinical Tissue-Analysis Data Supporting Potential Neuroprotective Effect of ExoPTEN in Acute Spinal Cord Injury Animal Model Tissue analysis showed significantly higher numbers of myelin-positive cells in ExoPTEN-treated animals compared with controls, providing additional preclinical biological support for previously…
globenewswire.com NurExone Announces Binding MOU with Made Scientific for U.S. GMP Manufacturing and Commercial Supply Partnership The Signed MOU Targets Initial GMP Exosome Batches in H1 2027 to Support NurExone's Clinical Pipeline and Planned Commercial Production The Signed MOU Targets Initial GMP Exosome Batches in H1 2027…
globenewswire.com NurExone Launches Bioprocess Optimization Initiative to Support Commercial and Clinical Readiness TORONTO and HAIFA, Israel, July 30, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX, OTCQB: NRXBF, FSE: J90) (“NurExone” or the “Company”), a biotechnology company developing exosome-based…
globenewswire.com Corporate Updates – NurExone appoints Mr. David Stolick to the Board of Directors TORONTO, Ontario and HAIFA, Israel, July 29, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company…
globenewswire.com NurExone Announces Closing of Non-Brokered Private Placement TORONTO, Ontario and HAIFA, Israel, June 30, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company…
globenewswire.com Exo-Top, NurExone's wholly owned U.S. Subsidiary, Enters Into Binding MOU For Naïve Exosome Distribution in Mexico TORONTO, Ontario and HAIFA, Israel, June 25, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company…
globenewswire.com NurExone Announces First Quarter 2026 Financial Results and Provides Corporate Update TORONTO, Ontario and HAIFA, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company…
thenewswire.com Water Tower Research Publishes Initiation of Coverage Report on NurExone Biologic, Inc., “A Novel Exosome Therapy Platform at the Frontier of CNS Regeneration” May 21, 2026, ST. PETERSBURG, FL – Water Tower Research (www.watertowerresearch.com) has published an Initiation of Coverage Report on NurExone Biologic, Inc. (TSXV: NRX/OTCQB: NRBXF) titled, “A…
globenewswire.com NurExone Receives Notice of Patent Grant in South Korea Covering ExoPTEN Technology Expands intellectual property protection in a strategically important market for the Company's lead exosome-based therapy targeting nerve repair and functional recovery Expands intellectual property…
globenewswire.com NurExone Advances to Stage 2 of EU-Backed EIT Health Catapult Programme 2026 TORONTO, Ontario and HAIFA, Israel, May 14, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing…
globenewswire.com Australian Patent Granted to NurExone Covering Stem Cell-Derived Exosome Production Sheba medical center researcher to present NurExone's exosome optic nerve regeneration work at ISCEV@Denver Sheba medical center researcher to present NurExone's exosome optic nerve regeneration work…